サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758967

卵管がん治療の世界市場

Fallopian Tube Cancer Therapeutics

出版日
ページ情報
英文 139 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
卵管がん治療の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 139 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

卵管がん治療の世界市場は2030年までに30億米ドルに到達

2024年に16億米ドルと推定される卵管がん治療の世界市場は、2024～2030年の分析期間にCAGR 10.7％で成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 11.7％を記録し、分析期間終了までに22億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間中CAGR 8.2％と推定されます。

米国市場は推定4億2,910万米ドル、中国はCAGR9.7％で成長予測

米国の卵管がん治療市場は、2024年に4億2,910万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.7%で推移し、2030年には4億6,140万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.6%と8.6%と予測されています。欧州では、ドイツがCAGR 8.3%で成長すると予測されています。

世界の卵管がん治療市場- 主要動向と促進要因のまとめ

卵管がん治療を形成する最新の治療進歩とは？

卵管がん治療の状況は、精密医療と分子標的治療におけるブレークスルーに牽引され、大きな革新を経験しています。最も注目すべき進歩は、オラパリブやニラパリブなどのPARP阻害剤の導入です。オラパリブはもともと卵巣がん用に開発されたが、遺伝的プロファイル、特にBRCA変異が重複しているため、現在では卵管の高悪性度漿液性がんに有望視されています。研究者たちは、次世代シークエンシング（NGS）の役割を拡大し、実用的な遺伝子マーカーに基づいて患者を層別化することで、有効性が向上し全身毒性がより少ない、よりオーダーメイドのレジメンを可能にしています。

免疫療法もまた、ゆっくりとではあるが大きな進歩を遂げています。PD-1やCTLA-4を標的とするチェックポイント阻害剤は、まだ初期段階の試験であるが、再発例や治療抵抗性例において化学療法との併用や単剤療法として評価されています。このような技術革新は、卵管悪性腫瘍特有の生物学的特徴や病期分類を考慮した腫瘍学ガイドラインの更新に支えられ、徐々にアカデミックセンターを越えて、より広範な臨床へと移行しつつあります。術中蛍光ガイド下手術とリアルタイム画像診断の進歩により、腫瘍切除の精度が向上し、患者の転帰が改善し、再発が最小限に抑えられています。

タイムリーな介入をサポートする診断エコシステムはどのように進化しているか？

卵管がんの治療における重要な課題は、非特異的な症状や解剖学的に不明瞭なために早期発見が困難であることです。しかし、診断エコシステムは、予測バイオマーカー、リキッドバイオプシー、人工知能を搭載した画像診断ツールに注目が集まるにつれ、再調整されつつあります。循環腫瘍DNA（ctDNA）やエクソソームを分析するリキッドバイオプシーは、高リスク集団、特に家族性がん症候群の集団における悪性腫瘍を検出する可能性があるとして、臨床研究において人気を集めています。これらの低侵襲診断法をNGSと統合すれば、TP53、BRCA1/2、PALB2などの遺伝子の変異を疾患進行の早期段階で同定することができます。

これと並行して、画像診断も高解像度の経膣超音波検査、造影MRI、AI増強PET検査などの採用により進歩しています。これらのツールは、卵管がんと密接に関連する卵巣悪性腫瘍や腹膜悪性腫瘍との鑑別に役立っています。コンパニオン診断薬も出現しており、特定の治療薬と患者の反応性を予測するバイオマーカーアッセイを結びつけています。精密診断をサポートするために償還モデルが進化するにつれて、より多くの患者がこれらの先進的なツールを利用できるようになり、タイムリーで的を絞った治療介入が容易になると予想されます。

成長を牽引する市場力学と地域パターンとは？

世界の卵管がん治療市場は、疫学的シフト、規制改革、ヘルスケアインフラ整備の複雑な相互作用によって形成されています。北米は、臨床試験、規制当局の承認、先端治療薬の入手可能性という点で市場をリードしているが、これは主に確立されたがん研究センターと有利な保険適用によるものです。欧州は、ドイツや英国のような国々が、集団全体のスクリーニング・イニシアチブとゲノム・プロファイリング・プログラムに投資しており、その後に続いています。アジア太平洋では、市場はまだ成熟途上にあるが、がんに対する意識の高まり、がん罹患率の上昇、がん診断や治療へのアクセスに対する政府主導の投資により、大きな可能性を示しています。

バイオ製薬企業との提携や産学連携がイノベーションのパイプラインに拍車をかけています。複数の多国籍医薬品メーカーが、希少な婦人科系がんに特化したバイオテクノロジー企業とライセンシング契約を結んでおり、がん領域のポートフォリオ拡大を目指しています。標的治療薬へのアクセスが制限されがちな低所得国では、価格圧力が依然として制約となっています。しかし、バイオシミラーや段階的価格設定モデルの導入により、コスト面での障壁が緩和されることが期待されます。患者支援団体やがん財団の存在は、資金提供、啓発キャンペーン、有望な治療法の早期承認に向けたロビー活動を通じて、治療ガイドラインやアクセスにさらなる影響を与えています。

治療薬市場の拡大を牽引する力とは？

卵管がん治療市場の成長は、臨床、技術、経済の各領域に収斂するいくつかの要因によって牽引されています。主要な促進要因の1つは、婦人科腫瘍学研究や試験デザインに卵管がんが含まれるようになってきたことです。これまで卵巣がんと一括りにされてきた卵管がんは、現在では別個の病理学的存在として認識されつつあり、研究開発への集中的な取り組み、患者登録の拡大、病期分類基準の精緻化につながっています。この分類の転換は、製薬会社や研究機関が専用の治療開発への投資を正当化するのに役立っています。

もう一つのきっかけは、個別化医療とバイオマーカー主導型治療の適用範囲の拡大です。BRCA変異や相同組換え欠損症（HRD）のスクリーニングが日常的に行われるようになったことで、層別化された治療アプローチが可能になり、試行錯誤の処方が減り、無増悪生存率が向上しています。さらに、国際的ながん臨床試験の継続的な展開により、地域間の治療選択肢が拡大し、標的薬剤の承認プロセスが加速しています。

医療システムの近代化-特に新興国において-は、それを支える役割を果たしています。ゲノム検査機能やデジタルヘルスツールを備えた病院が増えるにつれて、先進的治療薬の普及が進むと予想されます。腫瘍学会や国際保健機関が主導する教育キャンペーンは、患者の意識を向上させ、早期診断を促進し、AIを活用した臨床意思決定支援ツールは、腫瘍医を最適な治療アルゴリズムへと導いています。このようなエコシステム全体の改善により、卵管がん治療市場は持続的な成長を遂げつつあり、患者の転帰と商業的実行可能性の両面で長期的な影響が期待されます。

セグメント

製品（標的療法、化学療法）;エンドユース（病院エンドユース、クリニック＆外来手術センターエンドユース、その他エンドユース）

調査対象企業の例

  • AbbVie Inc.
  • Advenchen Laboratories LLC
  • AiVita Biomedical Inc.
  • Alkermes plc
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals Inc.
  • Celsion Corporation
  • Compugen Ltd.
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • Genentech Inc.
  • Genmab A/S
  • ImmunoGen Inc.
  • Janssen Research & Development（Johnson & Johnson）
  • Merck & Co., Inc.
  • OncoQuest Pharmaceuticals Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Syndax Pharmaceuticals Inc.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP36879

Global Fallopian Tube Cancer Therapeutics Market to Reach US$3.0 Billion by 2030

The global market for Fallopian Tube Cancer Therapeutics estimated at US$1.6 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 10.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 11.7% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$429.1 Million While China is Forecast to Grow at 9.7% CAGR

The Fallopian Tube Cancer Therapeutics market in the U.S. is estimated at US$429.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$461.4 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Fallopian Tube Cancer Therapeutics Market - Key Trends & Drivers Summarized

What Are the Latest Therapeutic Advances Reshaping Fallopian Tube Cancer Treatment?

The landscape of fallopian tube cancer therapeutics is experiencing significant innovation, driven by breakthroughs in precision medicine and molecular-targeted therapies. Among the most notable advancements are the incorporation of PARP inhibitors such as olaparib and niraparib, originally developed for ovarian cancer, but now showing promise for high-grade serous carcinomas of the fallopian tube due to overlapping genetic profiles, especially BRCA mutations. Researchers are expanding the role of next-generation sequencing (NGS) to stratify patients based on actionable genetic markers, allowing for more tailored regimens with improved efficacy and fewer systemic toxicities.

Immunotherapy is also making slow yet significant strides. Although still in early-stage trials, checkpoint inhibitors targeting PD-1 and CTLA-4 have been evaluated in combination with chemotherapy or as monotherapies in recurrent and treatment-resistant cases. These innovations are gradually moving beyond academic centers into broader clinical practice, supported by updated oncology guidelines that acknowledge the unique biology and staging considerations of fallopian tube malignancies. Advances in intraoperative fluorescence-guided surgery and real-time diagnostic imaging are improving the precision of tumor resection, enhancing patient outcomes, and minimizing recurrence.

How Is the Diagnostic Ecosystem Evolving to Support Timely Intervention?

A critical challenge in the treatment of fallopian tube cancer is the difficulty in early detection due to nonspecific symptoms and anatomical obscurity. The diagnostic ecosystem, however, is being recalibrated with a growing focus on predictive biomarkers, liquid biopsies, and artificial intelligence-powered imaging tools. Liquid biopsies analyzing circulating tumor DNA (ctDNA) and exosomes are gaining traction in clinical research for their potential to detect malignancies in high-risk populations, especially those with familial cancer syndromes. When integrated with NGS, these minimally invasive diagnostics can help identify mutations in genes such as TP53, BRCA1/2, and PALB2 at earlier stages of disease progression.

In parallel, diagnostic imaging is advancing through the adoption of high-resolution transvaginal ultrasonography, contrast-enhanced MRI, and AI-enhanced PET scans. These tools are proving instrumental in differentiating fallopian tube carcinoma from closely related ovarian and peritoneal malignancies. Companion diagnostics are also emerging, linking specific therapeutic agents with biomarker assays that predict patient responsiveness. As reimbursement models evolve to support precision diagnostics, more patients are expected to access these advanced tools, facilitating timely and targeted therapeutic intervention.

Which Market Dynamics and Regional Patterns Are Steering Growth?

The global fallopian tube cancer therapeutics market is shaped by a complex interplay of epidemiological shifts, regulatory reforms, and healthcare infrastructure development. North America leads the market in terms of clinical trials, regulatory approvals, and availability of advanced therapeutics, largely due to established cancer research centers and favorable insurance coverage. Europe follows closely, with countries like Germany and the UK investing in population-wide screening initiatives and genomic profiling programs. In Asia-Pacific, the market is still maturing but shows substantial potential owing to increasing awareness, rising cancer incidence, and government-led investments in oncology diagnostics and treatment access.

Biopharmaceutical partnerships and academic-industry collaborations are fueling innovation pipelines. Several multinational drugmakers are entering licensing deals with biotech firms focused on rare gynecological cancers, aiming to expand their oncology portfolios. Pricing pressures remain a constraint in lower-income economies, where access to targeted therapies is often limited. However, the introduction of biosimilars and tiered pricing models is expected to alleviate some cost barriers. The presence of patient advocacy groups and cancer foundations is further influencing treatment guidelines and access through funding, awareness campaigns, and lobbying for regulatory fast-tracking of promising therapies.

What Forces Are Driving the Expansion of the Therapeutics Market?

The growth in the fallopian tube cancer therapeutics market is driven by several factors that converge across clinical, technological, and economic domains. One of the key drivers is the growing inclusion of fallopian tube cancer in gynecologic oncology research and trial designs. Historically grouped with ovarian cancer, fallopian tube carcinoma is now being recognized as a distinct pathological entity, leading to focused R&D efforts, expanded patient registries, and refined staging criteria. This classification shift is helping pharmaceutical companies and research institutions justify investment in dedicated therapeutic development.

Another catalyst is the broadening application of personalized medicine and biomarker-led therapy. The routine screening for BRCA mutations and homologous recombination deficiency (HRD) is enabling stratified treatment approaches, reducing trial-and-error prescriptions, and improving progression-free survival rates. Furthermore, the continued rollout of global oncology clinical trials is expanding treatment options across geographies, accelerating the regulatory approval process for targeted agents.

Health system modernization-particularly in emerging economies-is playing a supporting role. As more hospitals are equipped with genomic testing capabilities and digital health tools, the penetration of advanced therapeutics is expected to rise. Educational campaigns led by oncology associations and global health bodies are improving patient awareness and driving early-stage diagnosis, while AI-powered clinical decision support tools are guiding oncologists toward optimal treatment algorithms. These ecosystem-wide improvements are setting the stage for sustained growth in the fallopian tube cancer therapeutics market, with promising long-term implications for both patient outcomes and commercial viability.

SCOPE OF STUDY:

The report analyzes the Fallopian Tube Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Targeted Therapy, Chemotherapy); End-Use (Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Advenchen Laboratories LLC
  • AiVita Biomedical Inc.
  • Alkermes plc
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals Inc.
  • Celsion Corporation
  • Compugen Ltd.
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • Genentech Inc.
  • Genmab A/S
  • ImmunoGen Inc.
  • Janssen Research & Development (Johnson & Johnson)
  • Merck & Co., Inc.
  • OncoQuest Pharmaceuticals Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Syndax Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Fallopian Tube Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Targeted Therapy Approaches Enhance Treatment Efficacy
    • Increased Research on BRCA Gene Mutations Expands Therapeutic Development Opportunities
    • Growing Awareness of Early Detection Methods Drives Demand for Diagnostic Tools
    • Integration of Artificial Intelligence in Drug Discovery Accelerates Therapeutic Innovations
    • Development of Personalized Medicine Strategies Strengthens Treatment Outcomes
    • Expansion of Clinical Trials for Novel Agents Propels Market Growth
    • Government Funding and Grants Support Research in Rare Gynecological Cancers
    • Collaborations Between Pharmaceutical Companies and Research Institutions Foster Innovation
    • Emergence of Immunotherapy as a Promising Treatment Modality Gains Traction
    • Regulatory Approvals of New Drugs Enhance Accessibility to Advanced Therapies
    • Integration of Companion Diagnostics Improves Patient Stratification
    • Rising Incidence Rates Highlight Need for Effective Therapeutic Options
    • Technological Innovations in Drug Delivery Systems Improve Treatment Precision
    • Expansion of Healthcare Infrastructure in Emerging Markets Increases Treatment Availability
    • Patient Advocacy and Support Groups Raise Awareness and Funding for Research
    • Adoption of Telemedicine Platforms Facilitates Access to Specialized Care
    • Pharmaceutical Companies' Focus on Orphan Drug Designation Encourages Development
    • Integration of Genomic Data in Clinical Decision-Making Enhances Treatment Personalization
    • Strategic Partnerships and Mergers Accelerate Pipeline Development
    • Implementation of Value-Based Pricing Models Influences Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fallopian Tube Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Clinics & Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Clinics & Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Fallopian Tube Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by Product - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Fallopian Tube Cancer Therapeutics by Product - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Fallopian Tube Cancer Therapeutics by End-Use - Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Fallopian Tube Cancer Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics & Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION